Back to GetFilings.com



FORM 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

   (Mark One)
X      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)
                 OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 27, 2003

OR

__     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                 OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission file number 000-23249

PRIORITY HEALTHCARE CORPORATION
(Exact name of registrant as specified in its charter)

         Indiana
(State or other jurisdiction of
incorporation or organization)

              250 Technology Park
               Lake Mary, Florida
(Address of principal executive offices)
                35-1927379
  (I.R.S. Employer Identification No.)



                      32746
                  (Zip Code)

        Registrant’s telephone number, including area code: (407) 804-6700

  No Change
  (Former name, former address and former fiscal year,
if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X        No __

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes X        No __

As of October 24, 2003, the number of shares outstanding of each of the issuer’s classes of common stock were as follows:

Class A Common Stock – 6,712,325

Class B Common Stock – 36,563,386


PART 1 — FINANCIAL INFORMATION

Item 1. Financial Statements.

PRIORITY HEALTHCARE CORPORATION
CONSOLIDATED STATEMENTS OF EARNINGS
(000‘s omitted, except share data)
(unaudited)

  Nine-month
period ended
September 27,
2003

Nine-month
period ended
September 28,
2002

Three-month
period ended
September 27,
2003

Three-month
period ended
September 28,
2002

Net sales     $ 1,064,891   $ 863,465   $ 362,855   $ 306,009  
Cost of products sold    947,450
   765,401
   323,483
   270,671
 
Gross profit    117,441    98,064    39,372    35,338  
Selling, general and administrative expense    56,506    46,892    18,981    16,458  
Depreciation and amortization    3,137    1,980    1,127    677  
     
   
   
   
 
Earnings from operations    57,798    49,192    19,264    18,203  
Interest income    1,058
   2,046
   246
   508
 
Earnings before income taxes    58,856    51,238    19,510    18,711  
Provision for income taxes    22,071
   19,214
   7,316
   7,016
 
Net earnings   $ 36,785   $ 32,024   $ 12,194   $ 11,695  
     
   
   
   
 
Earnings per share:                   
        Basic   $ .85   $ .73   $ .28   $ .27  
        Diluted   $ .84   $ .72   $ .28   $ .27  
Weighted average shares outstanding:  
       Basic    43,452,856    43,781,392    43,259,781    43,597,491  
        Diluted    44,024,550    44,447,572    43,773,728    44,032,375  

        See accompanying notes to consolidated financial statements.

2


PRIORITY HEALTHCARE CORPORATION
CONSOLIDATED BALANCE SHEETS
(000‘s omitted, except share data)

  (unaudited)
September 27,
2003

December 28,
2002

ASSETS:            
Current assets:  
     Cash and cash equivalents   $ 47,088   $ 37,031  
     Restricted cash    7,000    --  
     Marketable securities    21,675    46,337  
     Receivables, less allowance for doubtful accounts of $6,073 and $5,437, respectively    181,979    163,688  
     Finished goods inventory    99,553    108,604  
     Deferred income taxes    3,221    3,221  
     Other current assets    17,878    14,667  


     378,394    373,548  
Fixed assets, net    23,962    13,749  
Restricted cash    2,000    --  
Other assets    4,000    4,780  
Intangibles, net    105,402    92,785  


               Total assets   $ 513,758   $ 484,862  


LIABILITIES AND SHAREHOLDERS' EQUITY:           
Current liabilities:  
     Accounts payable   $ 157,768   $ 142,666  
     Other current liabilities    24,154    45,448  


     181,922    188,114  
Other liabilities    2,000    --  
Deferred income taxes    2,321    2,321  


               Total liabilities    186,243    190,435  


Commitments and contingencies (note 5)

          
Shareholders' equity:  
     Preferred stock, no par value, 5,000,000 shares authorized, none issued and outstanding    --    --  
     Common stock  
          Class A, $0.01 par value, 55,000,000 shares authorized, 6,716,678 and 6,880,497           issued and outstanding, respectively    67    69  
          Class B, $0.01 par value, 180,000,000 shares authorized, 38,680,640 and 38,516,821            issued, respectively    387    385  
          Additional paid in capital    188,907    187,158  
          Retained earnings    173,858    137,073  


     363,219    324,685  

Less: Class B Common unearned restricted stock, 53,000
         and 53,000 shares, respectively
    (715 )  (1,291 )
        Class B Common stock in treasury (at cost), 2,129,297
        and 1,884,078 shares, respectively
    (34,989 )  (28,967 )


               Total shareholders' equity    327,515    294,427  


               Total liabilities and shareholders' equity   $ 513,758   $ 484,862  


        See accompanying notes to consolidated financial statements.

3


PRIORITY HEALTHCARE CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(000‘s omitted)
(unaudited)

  Nine-month
period ended
September 27,
2003

Nine-month
period ended
September 28,
2002

Cash flow from operating activities:            
     Net earnings   $ 36,785   $ 32,024  
        Adjustments to reconcile net earnings to net cash provided by operating activities:          
               Depreciation and amortization    3,137    1,980  
               Provision for doubtful accounts    1,842    1,749  
               Tax benefit from stock option exercises    422    892  
               Compensation expense on restricted stock grants    619      
        Change in assets and liabilities, net of acquisitions:  
               Receivables    (20,133 )  (36,789 )
               Finished goods inventory    9,308    (3,217 )
               Accounts payable    12,450    1,513  
               Other current assets and liabilities    (17,560 )  8,688  


                 Net cash provided by operating activities    26,870    6,840  


Cash flow from investing activities:          
     Sales, net of purchases, of marketable securities    24,662    55,500  
     Restricted cash for acquisition of business    (9,000 )    
     Purchases of fixed assets    (11,588 )  (5,912 )
     Decrease (increase) in other assets    3,075    (8,649 )
     Acquisition of businesses    (15,226 )  (32,881 )


                 Net cash (used) provided by investing activities    (8,077 )  8,058  


Cash flow from financing activities:          
     Proceeds from stock option exercises    1,534    3,465  
     Purchases of treasury stock    (10,270 )  (13,190 )


                 Net cash used by financing activities    (8,736 )  (9,725 )


Net increase in cash    10,057    5,173  
Cash and cash equivalents at beginning of period    37,031    32,758  


Cash and cash equivalents at end of period   $ 47,088   $ 37,931  


Supplemental non-cash investing and financing activities:          
     Acquisition liabilities   $ 9,000   $ 1,176  
     Stock issued in connection with acquisition    1,500    5,000  
     Stock issued in connection with investment    3,500      

        See accompanying notes to consolidated financial statements.

4


PRIORITY HEALTHCARE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

1.     The accompanying consolidated financial statements have been prepared by the Company without audit. Certain information and footnote disclosures, including significant accounting policies, normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The Company believes that the financial statements for the three-month and nine-month periods ended September 27, 2003 and September 28, 2002 include all necessary adjustments for fair presentation. Results for any interim period may not be indicative of the results for the entire year.

2.     A reconciliation of the basic and diluted weighted average shares outstanding is as follows for the three-month and nine-month periods ended September 27, 2003 and September 28, 2002:
  (000's omitted)
  Nine-month
period ended
September 27,
2003

Nine-month
period ended
September 28,
2002

Three-month
period ended
September 27,
2003

Three-month
period ended
September 28,
2002

Weighted average number of Class A and Class B Common shares outstanding used as the denominator in the basic earnings per share calculation    43,453    43,781    43,260    43,597  
                       
Additional shares assuming exercise of dilutive stock options    518    667    481    435  
                       
Additional shares assuming unearned restricted stock is earned    33    --    33    --  
                       
Additional shares assuming contingently issuable shares related to acquisitions are issued    21    --    --    --  




Weighted average number of Class A and Class B Common and equivalent shares used as the denominator in the diluted earnings per share calculation    44,025    44,448    43,774    44,032  




  Options to purchase 3.6 million and 2.9 million shares with exercise prices greater than the average market prices of common stock during the three-month periods ended September 27, 2003 and September 28, 2002 were outstanding at September 27, 2003 and September 28, 2002, respectively. These options were excluded from the respective computations of diluted earnings per share because their effect would be anti-dilutive.

3.     In December 2002, SFAS No. 148, “Accounting for Stock-Based Compensation – Transition and Disclosure” was issued. This statement provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. This statement also amends the disclosure requirements of SFAS No. 123, “Accounting for Stock-Based Compensation,” to require prominent disclosures about the method of accounting for stock-based compensation and the effect of the method used on reported results. Finally, this statement amends Accounting Principles Board Opinion No. 28, “Interim Financial Reporting,” to require disclosure about those effects in interim financial information. As required, the Company adopted this statement effective in 2002. The adoption did not have a material impact on the Company’s consolidated results of operations or financial position.

5




  In accordance with the provision of SFAS No. 123, the Company has elected to follow Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees,” and related Interpretations in accounting for its stock option plans. Accordingly, the Company uses the intrinsic-value method of accounting for stock options granted to employees and does not currently recognize compensation expense for its stock option awards to employees in the consolidated statements of earnings. If the Company had elected to recognize compensation expense based on the fair value of the options at the grant date as prescribed by SFAS No. 123, pro forma net income and earnings would have been:

  (000's omitted, except share data)
  Nine-month
period ended
September 27,
2003

  Nine-month
period ended
September 28,
2002

  Three-month
period ended
September 27,
2003

  Three-month
period ended
September 28,
2002

 
Net earnings - as reported     $ 36,785   $ 32,024   $ 12,194   $ 11,695  
         Pro forma impact of Company option grants    (8,497 )  (8,142 )  (2,834 )  (2,728 )

 
 
 
 
Pro forma net earnings   $ 28,288   $ 23,882   $ 9,360   $ 8,967  

 
 
 
 
Pro forma earnings per share:                  
        Basic   $ 0.65   $ 0.55   $ 0.22   $ 0.21  
        Diluted   $ 0.64   $ 0.54   $ 0.21   $ 0.20